At D. Watson, a huge portion of our medical equipment (like BP monitors, glucometers, and nebulizers) and optical supplies relies on manufacturing out of China. When the factories shut down for the Lunar New Year, the disruption doesn't just last for the holiday week it creates a backlog that affects shipments well into March.
To hedge against this, we executed a heavy "Q1 Front-Load." Instead of our usual monthly rolling orders, we aggregated our forecasted demand for January, February, and March and pulled that entire order volume into late December. We essentially turned our Just-In-Time (JIT) model into a "Just-In-Case" model for that specific quarter.
Coordinating this meant having tough conversations with our procurement team in November to lock in production slots before the "pre-holiday rush" hit the Chinese factories.
The trade-off was cash flow pressure. By bringing three months of stock in at once, we tied up a significant amount of operating capital that could have been used for expansion or marketing elsewhere. We also stressed our warehousing capacity to its limit.
However, in the healthcare business, "out of stock" isn't just a missed sale it's a violation of trust. If a customer walks into D. Watson needing a nebulizer for a sick child, I cannot tell them to come back when the factories re-open. We accepted the hit to our liquidity to ensure our shelf reliability remained 100%.
